MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorWake Forest University Health Sciences
About this trial
The purpose of this research study is to find out if the use of magnesium in addition to Metoprolol, a rate controlling medication that you would be offered in the Emergency Department today unrelated to this study, will help reduce your high heart rate (rapid ventricular response).
Eligibility criteria
Qualifiers
Age > 18 years or older
Able to provide informed consent
Primary diagnosis atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR) greater than or equal to 120 beats per minute
Metoprolol as rate control agent
Disqualifiers
Hemodynamically unstable patients (SBP <90, MAP <65)
Impaired consciousness
Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
Trial design
Treatments tested in this trial
- Magnesium Sulfate 2g
- Magnesium Sulfate 4g
- Saline (0.9% NaCl)
Treatment groups
196 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov